Quick Answer
Oruka Therapeutics, Inc. reported Net Income Loss of -$105.43 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed a decrease of -25.9% in Net Income Loss from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2004 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: -$4.43 million | Q4 2017: -$4.20 million | Q1 2018: -$2.74 million | Q2 2018: -$2.12 million | Q3 2018: -$1.59 million | Q4 2018: -$1.49 million | Q1 2019: -$1.66 million | Q2 2019: -$1.44 million | Q3 2019: -$1.16 million | Q4 2019: -$1.23 million | Q1 2020: -$1.32 million | Q2 2020: -$1.30 million | Q3 2020: -$1.99 million | Q4 2020: -$5.13 million | Q1 2021: -$4.10 million | Q2 2021: -$4.83 million | Q3 2021: -$4.71 million | Q4 2021: -$5.68 million | Q1 2022: -$3.27 million | Q2 2022: -$3.15 million | Q3 2022: -$2.33 million | Q4 2022: -$1.17 million | Q1 2023: -$1.35 million | Q2 2023: -$1.48 million | Q3 2023: -$1.42 million | Q4 2023: -$1.09 million | Q1 2024: -$7.08 million | Q2 2024: -$22.24 million | Q3 2024: -$28.62 million | Q1 2025: -$21.00 million | Q2 2025: -$24.57 million | Q3 2025: -$30.28 million.
- Over the full 22 years of available data (2004 to 2025), Oruka Therapeutics, Inc.'s Net Income Loss has declined by 20,532.7%.
- Historical annual values: Fiscal year 2025: -$105.43 million | Fiscal year 2024: -$83.72 million | Fiscal year 2023: -$5.34 million | Fiscal year 2022: -$9.93 million | Fiscal year 2021: -$19.32 million | Fiscal year 2020: -$9.74 million | Fiscal year 2019: -$5.48 million | Fiscal year 2018: -$7.93 million | Fiscal year 2017: -$18.49 million | Fiscal year 2016: -$16.44 million | Fiscal year 2015: -$11.45 million | Fiscal year 2014: -$9.69 million | Fiscal year 2013: -$6.94 million | Fiscal year 2012: -$4.32 million | Fiscal year 2011: -$5.36 million | Fiscal year 2010: -$8.42 million | Fiscal year 2009: -$9.14 million | Fiscal year 2008: -$19.43 million | Fiscal year 2007: -$13.99 million | Fiscal year 2006: -$5.24 million | Fiscal year 2005: -$1.46 million | Fiscal year 2004: -$511.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: